Research library

B

grade

Combination therapy with GnRHa and rhGH may improve height outcomes in girls with CPP, especially those with severe height impairment, but results are specific to the studied population.

GnRHa + rhGH group AHG: 1.72 SDS (1.24, 2.59).

summary

D

grade

Recombinant human growth hormone (rhGH) may offer a new avenue for managing growth retardation in pediatric inflammatory bowel disease, but more research is needed to confirm its efficacy and safety.

summary

A

grade

rhGH therapy shows the strongest growth response in children with complete GHD, especially when started early and guided by IGF-1 levels.

Baseline IGF-1 SDS was lowest in GHD (-2.9 ± 1.1) compared with ISS (-1.5 ± 1.2) and SGA (-1.3 ± 1.1; p<0.001).

summary

C

grade

Denosumab and rhGH show potential for periodontal regeneration, but further human studies are needed to confirm their clinical applicability.

Facial bone height: 11.97 ± 0.05 mm for DNS vs. 9.96 ± 0.06 mm for rhGH, P = 0.004.

summary

B

grade

Integrating genetic, biomarker, and AI tools can enhance individualized rhGH therapy in pediatric growth disorders, but further validation is needed.

IGF-1/IGFBP-3 M ratio sensitivity 87.5%, specificity 83.0% for GH deficiency.

summary

B

grade

An AI-driven approach successfully created a Data Mart for AGHD, potentially enhancing real-world data analysis but requires broader validation.

188 validated AGHD patients out of 210 identified.

summary

C

grade

This study presents a promising ultra-long-acting growth hormone mimetic with extended efficacy in rats, but human trials are needed to determine clinical relevance.

227-fold difference in dissociation rates between neutral and acidic conditions.

summary

B

grade

Increased exposure to certain phthalates during pregnancy may be associated with shorter anogenital distance in female infants at 5 months, indicating a potential impact on reproductive development.

Each quartile increase in the phthalate/replacement mixture was associated with -4.13 mm/m shorter AGIShort (95% CI: -7.22, -1.05) in 5-month-old females.

summary

B

grade

Switching from daily GH to once-weekly somapacitan showed no significant difference in total lean mass but did improve some functional outcomes.

mean difference -0.2 kg in total lean mass change at week 52, 95% CI -1.5 to 1.1

summary

B

grade

Switching from daily growth hormone to once-weekly somapacitan did not significantly change total lean mass but showed improvements in functional outcomes.

mean difference -0.2 kg in total lean mass change at week 52, 95% CI -1.5 to 1.1

summary

B

grade

In a child with severe growth hormone deficiency and an MC4R variant, rhGH therapy led to an unexpected increase in IGF-1 levels and height velocity, suggesting the need for careful monitoring and dose adjustments.

IGF-1 levels increased from -3.35 SDS to +8.00 SDS.

summary

A

grade

Jintrolong may provide a slight improvement in growth outcomes without increased safety risks compared to other GH treatments, but the clinical impact is unclear.

Jintrolong HV: MD 0.86 cm/year; 95% CI, 0.13 to 1.6.

summary

B

grade

rhGH and preemptive transplantation are associated with improved growth in pediatric kidney transplant recipients, but ongoing monitoring is crucial for optimizing outcomes.

Mean height SDS improved from -2.08 to -1.6 over two years post-KTx.

summary

D

grade

A significant number of clinical trials are ongoing against SARS-CoV-2, but only a small fraction focus on mortality, raising concerns about the relevance of many studies.

22.8% of studies assess mortality as a primary outcome.

summary

B

grade

Omnitrope® appears to improve height in children with growth hormone deficiency, with a majority experiencing mild to moderate adverse events.

+1.25 height SD score improvement in US patients after 3 years.

summary

A

grade

Non-weight-based low-dose somatropin withdrawal may limit bone accrual in adolescents with childhood-onset GH deficiency during transition.

0.53 % ± 5.9 LS BMD change in GH group vs 4.42 % ± 4.1 in GS group, p < 0.04.

summary

A

grade

This study could change how we manage growth hormone therapy in children with I-GHD, potentially allowing some to stop treatment safely without affecting their final height.

1° outcome: near FH SDS with an inferiority margin of 0.55 SD.

summary

B

grade

As of November 2024, only 13.6% of somatropin prescriptions were biosimilars, indicating limited adoption despite their availability.

13.6% biosimilar prescriptions for somatropin in November 2024.

summary

B

grade

Machine learning approaches provided limited improvements in predicting growth response to rhGH in iGHD, with no clear benefits in ISS patients.

R² ≈ 0.19 for ensemble ML models predicting 1-year ΔHSDS in iGHD.

summary

A

grade

Intrauterine Growth Hormone did not significantly improve endometrial thickness or clinical pregnancy rates in this trial, though there was a numerical trend toward increased biochemical pregnancies that warrants further investigation.

Final endometrial thickness did not differ significantly between groups.

summary

B

grade

In children with idiopathic short stature responsive to the IGF-1 generation test, rhGH therapy resulted in a statistically significant increase in height SDS, but the clinical relevance of this change is uncertain.

Mean height SDS increased from -2.90 ± 0.77 at baseline to -1.92 ± 0.90 at NFH (p < 0.001).

summary

B

grade

Somatropin shows a stronger association with growth impairment in females than in males, highlighting the importance of sex-disaggregated pharmacovigilance in pediatric therapies.

ROR 76.85, 95% CI 65.52-90.15 for females using somatropin.

summary

B

grade

This study indicates that rhGH therapy may enhance growth in children with ACAN variants, but further research is needed to confirm these results and understand long-term effects.

Growth velocity at 3, 6, 9, 12, and 18 months was significantly higher than baseline (all P < 0.05).

summary

B

grade

An interpretable machine learning model can predict which children with idiopathic short stature may not respond optimally to growth hormone therapy, potentially aiding in personalized treatment planning.

AUC of 0.897 in external validation cohort.

summary

B

grade

RhGH therapy did not show significant progression of nonfunctional PitNETs over 36 months in this small cohort of children.

Not reported in abstract.

summary